Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
STAT Plus: Pharma’s drug spending deflection By Bob Herman Biotech Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Capricor had previously said its drug, called deramiocel, hit its targets in a Phase 3 study Manage alerts for this article Email this article Share this article Sarah Silbiger/Getty Images By Jason Mast Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
EU’s Google fine risks triggering Trump as he gears up for more tariffs - politico.eu
The fine against the U.S. tech giant lands just as Washington prepares new duties that could put last year’s fragile trade truce to the test.
FDA still focused on Taylor Farms lettuce as Cyclospora source despite retracted test - NPR
Cyclosporiasis is a foodborne illness caused by contaminated food or water carrying the Cyclospora parasite. FDA officials have yet to figure out the source of the outbreak that the CDC says has sickened more than 1,600 people this summer.
Anthropic a obținut aprobarea pentru un acord de 1,5 miliarde de dolari
Anthropic poate în sfârșit să înceapă să plătească o grupare de autori și edituri care au dat în judecată laboratorul de inteligență artificială pentru încălcarea drepturilor de autor. Un judecător federal a aprobat luni acordul istoric de 1,5 miliarde de dolari al Anthropic, conform Reuters.